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ORIGINAL ARTICLE
Hepatocellular carcinoma (HCC) has been the
leading cause of cancer death in Taiwan in recent
years.1 The relationship between HCC and chronic
hepatitis B and C virus (HBV and HCV) infection
has been demonstrated in many studies.2–6 As
one of the most endemic areas for HBV infection,
Taiwan has implemented a number of public
health measures to prevent HBV and HCV infec-
tion. The most successful and notable is the
National Hepatitis B Vaccination Program, which
has achieved extraordinary success in reducing the
HBV prevalence rate in children born after the
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Background/Purpose: Hepatocellular carcinoma (HCC) has been the leading cause of cancer death in
Taiwan since the 1980s. A two-stage screening intervention was introduced in 1996 and has been imple-
mented in a limited number of hospitals. The present study assessed the costs and health outcomes asso-
ciated with the introduction of screening intervention, from the perspective of the Taiwanese government.
The cost-effectiveness analysis aimed to assist informed decision making by the health authority in Taiwan.
Methods: A two-phase economic model, 1-year decision analysis and a 60-year Markov simulation, was
developed to conceptualize the screening intervention within current practice, and was compared with 
opportunistic screening alone. Incremental analyses were conducted to compare the incremental costs
and outcomes associated with the introduction of the intervention. Sensitivity analyses were performed to
investigate the uncertainties that surrounded the model.
Results: The Markov model simulation demonstrated an incremental cost-effectiveness ratio (ICER) 
of NT$498,000 (US$15,600) per life-year saved, with a 5% discount rate. An ICER of NT$402,000
(US$12,600) per quality-adjusted life-year was achieved by applying utility weights. Sensitivity analysis
showed that excess mortality reduction of HCC by screening and HCC incidence rates were the most influ-
ential factors on the ICERs. Scenario analysis also indicated that expansion of the HCC screening interven-
tion by focusing on regular monitoring of the high-risk individuals could achieve a more favorable result.
Conclusion: Screening the population of high-risk individuals for HCC with the two-stage screening 
intervention in Taiwan is considered potentially cost-effective compared with opportunistic screening in
the target population of an HCC endemic area. [J Formos Med Assoc 2010;109(1):39–55]
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vaccination program was implemented.7 However,
HCC is still a major public health issue because
of the high prevalence of HBV infection in the
population born before the vaccination program.
Studies on screening for HCC have established
the effectiveness of early detection of HCC and a
reduction of HCC mortality.8–11 Abdominal ultra-
sound examination and serum alpha-fetoprotein
(AFP) testing, alone or in combination, also have
shown acceptable sensitivity and specificity in
screening for HCC.12–15 HCC screening has been
conducted in many endemic areas, such as Alaska,
Japan, and China.11,16,17 In particular, a two-stage
screening strategy, which comprises identifica-
tion and subsequent follow-up of high-risk indi-
viduals, was used in Japan since early 1980s 
and has been widely utilized in Taiwan since the
early 1990s.16,18 A research foundation in Taiwan
initiated a two-stage screening intervention in
1996. The stage 1 screening was to identify high-
risk individuals for HCC through mass screening
for HBV and HCV carriers by testing the presence
of hepatitis B surface antigen (HBsAg), hepatitis
B surface antibody (HBsAb), and hepatitis C an-
tibody. A key feature of the intervention is its 
emphasis on continuous surveillance of high-risk
individuals in stage 2 screening.
Cost-effectiveness of screening for HCC has
been a controversial issue with contradictory con-
clusions from different parts of the world.19–24
A number of economic evaluation studies have
been conducted to assess cost-effectiveness of
screening for HCC, mainly in patients with cir-
rhosis or chronic hepatitis C.19–22 Limited infor-
mation is available on HCC screening in patients
with chronic hepatitis B with or without cirrhosis,
particularly in hepatitis B endemic areas. Most
cost-effectiveness analysis studies have evaluated
HCC screening by comparing the costs and health
consequences between screening intervention and
its hypothetical counterpart of no screening.19,21,24
No studies have attempted to assess HCC
screening by considering the logistics of prag-
matic intervention. The aim of the present study
was to conduct a cost-effectiveness analysis of a
two-stage screening intervention, compared with
opportunistic screening, in current practice from
the perspective of the Taiwanese government.
Materials and Methods
Our study developed a two-phase economic
model to simulate the short- and long-term out-
comes for the introduction of the screening in-
tervention. The two-phase model consisted of a
1-year decision analytical model and a 60-year
Markov model. This model provided a more real-
istic assessment for implementing the two-stage
screening intervention, by taking into account the
screening participation rates of an existing small
scale intervention.
Description of intervention and its
comparator
The intervention was defined as a two-stage screen-
ing with an organized approach to identify HCC
high-risk individuals by mass screening cam-
paign and subsequent continuing surveillance for
HCC. The intervention consisted of a mass media
campaign, two stages of screening with systematic
follow-up, and diagnosis and treatment of HCC
once detected. Stage 1 screening was conducted
with a 1-day hepatitis/HCC screening session, as
part of a mass media campaign of the intervention,
which invited the target population (defined
below) to be tested for two risk factors, namely,
hepatitis B and C. The contents and frequency 
of on-going surveillance for HCC at the stage 
2 screening depended on clinical judgment.
Hepatitis B and C carriers with normal liver func-
tion and serum AFP results were scheduled to be
followed-up at 6-month intervals, while those
with evidence of active hepatitis and cirrhosis
were monitored at a closer interval of 3 months.
For every follow-up consultation, liver function
tests [alanine transaminase (ALT) and aspartate
transaminase (AST)], HCC tumor marker AFP, and
abdominal ultrasound were carried out. The dis-
tinguishing feature of the screening intervention
compared with current clinical practice was the
structured program delivery, with establishment
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of a local database and reminder system man-
aged by the screening hospitals.
As a result of limited funding of the screening
intervention by a private foundation, the scale of
the intervention was limited to a small proportion
of the overall target population. Prior to the in-
troduction of the screening intervention, oppor-
tunistic screening of patients for relevant risk
factors has been undertaken on an ad hoc basis in
usual clinical practice. The screening for HCC in
current practice used similar screening tools but
with less frequency, and vital screening tests (ab-
dominal ultrasound and AFP) were neglected on
most occasions. The screening alternatives under
comparison in this study were the new screening
intervention within such opportunistic screening,
compared with opportunistic screening alone in
current practice. A screening pathway for the inter-
vention and its relationship to current practice 
is illustrated in Figure 1. It was assumed that 
people who dropped out from the screening 
intervention continued opportunistic screening
as per current clinical practice in Taiwan.
Study population
The target population for the screening interven-
tion was all Taiwanese individuals born before
1984, the year when the National Hepatitis B
Vaccination Program was implemented. This target
population was considered at increased risk of
contacting HBV by vertical transmission, and
should be examined to determine the status of
hepatitis carriage and the risk of developing
HCC. In addition to hepatitis B as a risk factor
for HCC, hepatitis C was also assessed in the
screening intervention, although the infection
was less severe compared with hepatitis B. From
1996 to 1999, there were > 64,000 individuals
who participated in the screening intervention,
which accounted for approximately 0.4% of the
target population.
Compared with the target population for the
screening intervention, the patient cohort of our
study was limited and selected from one of 15
hospitals that participated in the screening inter-
vention from 1996 to 1999. This cohort was
screened in 1997 at one regional hospital located
in central Taiwan. A medical record review and
questionnaire survey was undertaken to investigate
HCC screening rates for the intervention. A hy-
pothetical cohort of 100,000 persons was used in
the economic model.
Analytic models
A two-phase economic model, a 1-year decision
analysis and a 60-year Markov cohort simulation
(Figure 2), was developed to assess the short- and
long-term costs and outcomes associated with
the introduction of the screening intervention.
The 1-year decision analysis illustrated the
two-stage screening that represented the screen-
ing participation in the selected hospital and op-
portunistic screening of current practice. The
Markov model simulated the long-term disease
progression for individuals with hepatitis B and C
following the 1-year decision analysis. A number
of health states that characterized the disease
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Recruitment
Stage 1 screening:
Identification of high-risk
individuals
Stage 2 screening:
Continuous surveillance for
HCC
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Figure 1. Screening pathway of the screening intervention
and current practice. HCC = hepatocellular carcinoma.
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Figure 2. Decision tree and Markov model.
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progression, e.g. chronic hepatitis, cirrhosis, HCC,
and death were specified in the Markov model.
The transition probabilities and the source of
these estimates are listed in Table 1.15–20,25–37
The underlining principle of the Markov model
is that an individual is always in one of a finite
number of health states and moves from one
state to another in one transition cycle, depend-
ing upon their disease progression. Death is the
only absorbing health state (or end state) in the
Markov model. Incremental analyses were per-
formed to calculate incremental cost-effectiveness
ratio (ICER) by comparing the introduction of
the screening intervention with current practice
without the screening intervention. The incremen-
tal analysis allowed a meaningful comparison of
the additional cost and benefit for one interven-
tion compared with the other. 
To make allowance for the differential timing
of costs and consequence, a discount rate of 5%
Table 1. Baseline values and the ranges in sensitivity analysis of transition probabilities for model inputs
Outcome inputs Baseline value Range
Sources of valuation/
reference*
Screening intervention
Stage 1† 0.047 0.010–0.100 screening database
Test positive for risk factors 0.260 0.150–0.300 screening database
Stage 2‡ 0.376 0.290–0.660 medical record review
Current practice
Opportunistic screening for risk factors 0.586 0.290–0.880 questionnaire survey
Opportunistic screening for HCC 
after intervention 0.286 0.140–0.430 questionnaire survey and
before intervention 0.200 0.100–0.300 medical record review
questionnaire survey
HCC detected (annual incidence)
In high-risk groups 0.003 0.001–0.019 4, 16, 25
Chronic hepatitis
without cirrhosis 0.001 0.001–0.003 16, 18, 26
with cirrhosis 0.032 0.014–0.068 25, 27, 28
Proportion of early-stage small HCC
With intervention screening 0.800 0.550–1.000 15, 16, 20
With opportunistic screening 0.110 0.080–0.180 8, 17
Without screening 0.009 0.000–0.010 8, 17
Prognosis of cirrhosis (annual incidence)
In high-risk groups 0.021 0.013–0.048 29, 30
Excess mortality (annual probability)
Chronic hepatitis 0.008 0.080–0.358 31
Cirrhosis 0.106 0.019–0.390 32, 33
Early HCC
First year 0.080 0.080–0.360 8, 17, 34
Subsequent year 0.186 0.075–0.261 34–36
Late HCC
First year 0.240 0.040–1.000 8, 17, 34, 37
Subsequent year 0.468 0.286–0.632 5, 34, 37
*Sources of data are selected predominantly from Taiwan, Hong Kong, China, and Japan; †denotes stage 1 screening rate; ‡denotes
stage 2 screening rate. HCC = hepatocellular carcinoma.
was used for the 60-year Markov model for costs
and outcomes.
To make the models tractable, a number of
simplifying assumptions with regard to clinical
decision algorithms, transition probabilities and
associated outcome scenarios were made: (1) the
sensitivity and specificity of screening tests, includ-
ing HBsAg, HBsAb, hepatitis C antibody, AFP,
and abdominal ultrasound, were assumed to be
100% (i.e. false-positives and false-negatives were
not considered in the model); (2) underlying
rates of risk factors were identical across the entire
population (i.e. persons in the screening inter-
vention, those taking opportunistic screening in
current practice, and those without screening at
all were assumed to have the same prevalence of
risk factors); (3) individuals who continued stage
2 screening withdrew from the intervention at a
rate of 5% per annum; (4) HCC and cirrhosis inci-
dence rates in the high-risk individuals were the
same as those in current practice; (5) seroconver-
sion from hepatitis virus antigen to protective
antibody did not occur in chronic hepatitis B and
C patients; (6) early-stage HCC cases received
treatment before progressing to late stage HCC; (7)
the proportion of early-stage, small-size HCC was
identical for groups with the same screening fre-
quency; and (8) HCC patients who received pal-
liative care died within 1 year after treatment.
Sources of data
Three major sources of outcome data were used:
(1) the screening database from the research foun-
dation that initiated the intervention; (2) results
from the medical record review and questionnaire
surveys that investigated the changes in screening
behavior after the introduction of the interven-
tion; and (3) published medical literature about
the natural history of chronic hepatitis and HCC.
These outcome data are presented in Table 1,
which specifies the baseline values and ranges for
each transitional probability of model inputs.
Cost assessments were based on three sources:
(1) National Health Insurance Benefit Schedule
in Taiwan; (2) National Health Insurance Research
Database in Taiwan; and (3) the screening 
program administrative data. The National
Health Insurance Benefit Schedule is a payment
scheme of National Health Insurance for health
care services based on discounted market prices,
with little co-payment and no government subsi-
dies. The National Health Insurance Research
Database is a research database based on a sys-
tematic sampling of the National Health Insur-
ance payment claims data. The results of cost
assessment are presented in Table 2 and details
of the costing exercise can be obtained from the
authors.
Outcome and cost analysis
Surrogate outcomes in the 1-year decision analysis
were screening participation rates and positive
rates for risk factors. Stage 1 screening rate re-
ferred to the percentage of the target population
that participated in the stage 1 screening session.
Stage 2 screening rate was defined as the propor-
tion of high-risk individuals, who had been
identified in stage 1, and returned to the hospital
to continue stage 2 HCC screening. Screening
rates for the intervention and current practice
were estimated based on medical record review
and survey results of our study. Positive rates for
risk factors were determined by the screening re-
sults from the selected patient cohort of our
study. Two final endpoint outcomes included
death averted in the 1-year decision analysis and
life-year saved (LYS) in the Markov model. Table
3 presents key effect differences (e.g. the percent-
age of early HCC detected and HCC survival)
from continuing screening in comparison to op-
portunistic screening.
Our study also employed a simple weighting
exercise to explore the quality-adjusted life year
(QALY) gained by using utility weights obtaining
from the Study of Burden of Disease and Injury
in Australia.38 The study used Dutch weights to
measure the severity of a wide range of health
conditions; a higher weight corresponding to a
higher severity of a given condition. The utility
weight in measuring the quality of life therefore
is the complement of the disability weight 
(1-disability). Self-reported quality of life by 
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patients with standard instruments (e.g. Euroqol-
5D, Short From-36) for the relevant health states
is considered more appropriate.43–45 However, use
of the Dutch weights, a utility weighting frame-
work across a wide range of conditions assessed
by clinicians, provided a consistent measurement
of quality of life for health states assessed in our
analysis. The utility weights applied to the health
states in the Markov model were derived from
one single Dutch disability weight or an average
of multiple disability weights. For example, a dis-
ability weight of 0.8 for liver cancer after inten-
tionally curative primary therapy and clinically
disease-free state was used for the utility weight
for small HCC. The utility weight for the health
state of cirrhosis was obtained from the average
of disability weights of 0.69 for compensated
liver cirrhosis and 0.16 for decompensated liver
cirrhosis. Other Dutch weights used in the
Markov model were: asymptomatic hepatitis
(1.00), chronic symptomatic carrier (0.64), non-
radically removed/disseminated/preterminal liver
cancer (0.17), and terminal phase liver cancer
(0.07).
Cost assessment included resource use associ-
ated with increasing awareness of the screening
Hepatocellular carcinoma screening in Taiwan
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Table 2. Comparison of costs between intervention and opportunistic screening in the first year*
Intervention No intervention
Unit cost Cost per Unit cost Cost per Resource use category
per case participant per case participant
Recruitment for screening $57 $57.4 – –
Stage 1 screening for risk factors
Intervention screening $810 $810.0 – –
Opportunistic screening – – $817 $817.0
Stage 1 subtotal – $867.4 – $817.0
Stage 2 HCC screening
Intervention screening $2903 $283.3 – –
Opportunistic screening $503 $0.3 $503 $26.1
Stage 2 subtotal – $283.6 – $26.1
Diagnosis for HCC $19,629 $16.6 $19,629 $16.6
Treatment for HCC
Small HCC, survived $113,725 $32.5 $113,725 $2.6
Large HCC, survived $106,908 $43.1 $106,908 $66.3
HCC, died after treatment in 1st year $127,662 $19.4 $127,662 $25.3
Follow-up for HCC
Small HCC $28,257 $8.1 $28,257 $0.6
Large HCC $36,166 $14.6 $36,166 $22.4
HCC, died in subsequent year $68,643 – $68,643 –
HCC subtotal – $134.3 – $133.9
Follow-up for cirrhosis
With HCC intervention screening $6,240 $11.3 $6240 –
With HCC opportunistic screening $3722 $11.2 $3722 $3.6
Without HCC screening $3092 – $3092 $11.9
Death from cirrhosis complication $90,270 $51.5 $90,270 $51.5
Cirrhosis subtotal – $73.9 – $67.0
Total – $1359.2 – $1043.9
*Data presented as New Taiwan Dollars.
intervention and recruitment of participants,
screening tests cost, and diagnosis, treatment
and follow-up of HCC if detected. We conducted
a micro-costing exercise for each resource 
input, by breaking down each cost item of an 
individual procedure with its unit cost and fre-
quency of unit utilized. Costs were then ana-
lyzed in three ways: (1) cost per case in each
phase of the screening pathway; (2) total cost 
for a hypothetical cohort of 100,000; and (3) 
average cost per person in the cohort. All costs
were valued in 1997 New Taiwan Dollars 
($NT).
Sensitivity analysis
Three kinds of sensitivity analysis were used to
test the robustness of the model and to investigate
the impact of various assumptions on ICERs. One-
way analysis was conducted for each of the model
input variables, such as screening participation
S.T.F. Shih, et al
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Table 3. Difference of continuing screening in the intervention and opportunistic screening in current practice from selective
published studies
Effect Continuing screening1 Opportunistic screening2 Reference
% early HCC detected*,†
Tang et al (1980) 56.8% 7.7% 8
Yang et al (1997) 76.8% 0% 17
89% (resectable) 11% (resectable)
Bolondi (2001) 80.4% (unifocal) 52.9% (unifocal) 20
Tang et al (1995) 29–50% 5
Zoli et al (1996) 76% (< 4 cm) 10
Sherman (1995) 46% 42
Pateron (1994) 43% 43
Oka (1994) 81% (< 5 cm) 15
Izzo (1998) 91% (asymptomatic) 44
Tsai (1997) 95% (< 5 cm) 27
Mima (1994) 55% (< 5 cm) 16
Survival rate†
Bolondi (2002) 3 yr: 45% r 3 yr: 31.7% 20
Tang (1980) 1 yr: 79.1% receiving surgical 1 yr: 14.8% in clinical patients 8
resection
1 yr: 45.2% receiving 
conservative treatment
2 yr: 16.4% 2 yr: 7.4%
3 yr: 28.9% 3 yr: 5.5%
Yang et al (1997) 1 yr: 88.1% 0% 17
Chen et al (2002) Mortality rate 41% lower in 25
screening attendee compared 
with non-attendee
Wun & Dickinson (2003) 5 yr: 52.7% with resected HCC 0% 46
Chen et al (1998) 1 yr: 40.1%
Mima et al (1994) 1 yr: 79.0% 41
3 yr: 43.8% 16
5 yr: 19.3%
7 yr: 15.4%
*Early HCC is defined differently between studies. Unless it is indicated (e.g. size, resectable, asymptomatic, or unifocal), the percentage has been reported
as early HCC without definition. †For studies without comparison in opportunistic screening, these studies only reported what they found in screening set-
tings. HCC = hepatocellular carcinoma.
rates, risk factor prevalence, disease transition
probabilities, mortality rates, and costs. Scenario
analysis was carried out to project the impact on
both costs and benefits of expanding the program
to a national level. The “what if” scenario analysis
attempted to determine what would be the most
cost-effective approach of expanding the screening
intervention to a wider extent by changing the
screening rates. The multivariate probabilistic
analysis (Monte Carlo simulation) using @RISK
software v4.5 (Palisade Corp., NY, USA) was per-
formed using distributions around uncertainties
for model parameters with 2000 iterations of
simulation.
Results
Costs
Table 2 compares the costs between the screen-
ing intervention and opportunistic screening 
for each phase of the screening pathway in the 
first year. The average cost per person in screening
intervention was NT$1359.2, compared with
NT$1043.9 in current practice with opportunistic
screening. The additional cost per person was mini-
mal in the first year.
With the introduction of the screening inter-
vention, the approximate total cost of NT$2.031
billion (undiscounted cost) was required for sur-
veillance, treatment and follow-up for HCC in 
a hypothetical cohort of 100,000 persons for 
60 years. For the opportunistic screening, the
total cost over 60 years was NT$1.979 billion
(undiscounted cost). Thus, the incremental cost
associated with the introduction of the screening
intervention was approximately NT$51 million
(undiscounted cost) per 100,000 persons. Expressed
in the present value, the total cost of the screening
program for 60 years was NT$29 million per
100,000 persons, discounted at 5%. This was
equivalent to a mean cost of NT$9147 per person
(discounted cost) with the intervention compared
with NT$8850 without. It corresponded to an in-
cremental mean cost of NT$297 per person for 
60 years. The minimal incremental cost suggested
that such two-stage screening intervention was
not expensive.
Outcomes
The participation rates obtained from the med-
ical record review and questionnaires indicated 
a higher proportion of high-risk individuals
(37.6%) continued to have HCC screening in the
screening intervention compared with current
practice (28.6%). In addition, a comparison be-
fore and after the introduction of the screening
intervention also showed that a higher proportion
of high-risk individuals took up HCC screening
after the introduction of the intervention. This
demonstrated a positive impact of the screening
intervention on the overall population becoming
more aware of the disease, and encouraging more
high-risk individuals to become engaged in con-
tinuous HCC surveillance.
A greater prevalence of cancer was identified
in the screening intervention as a result of early
detection of asymptomatic cases. The 1-year deci-
sion analysis showed that, in a cohort of 100,000
persons, 3.5 small HCCs would be detected with
the intervention compared with 1.8 without. Thus,
there were more early-stage small HCCs detected
by introducing the screening intervention; an ad-
ditional 1.8 early HCCs per 100,000 persons.
Consequently, 0.3 deaths per 100,000 persons
would be prevented by the screening intervention
in the first year (Table 4).
The 60-year Markov model indicated that 26
cases of early-stage HCC would be detected and
60 life years would be saved in a cohort of
100,000 persons discounted at 5% rate per
annum (Table 4). The health gains from short-
and long-term were minimal because of the rela-
tively small share of the target population that
the screening intervention was able to manage.
Scaling the health gain up to a national level, the
results would be 45 deaths averted in the first year
and 9000 LYSs for 60 years. When incorporating
the utility weights, the health gain of 1.2 QALYs
was demonstrated in the first year, and 74 QALYs
in the 60-year Markov model for a cohort of
100,000 persons.
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Cost-effectiveness analysis
The incremental analysis results of the 1-year de-
cision analysis and the Markov model simula-
tion are summarized in Table 4. The results of
the 1-year decision analysis indicated an ICER of
NT$2,091,000 per additional early-stage small
HCC detected and NT$13,063,000 per death
averted, associated with the introduction of the
screening intervention in the first year. For 
the 60-year Markov model, the results of ICERs
were NT$1,131,000 per small HCC detected,
NT$498,000 per LYS and NT$402,000 per QALY.
Sensitivity analysis
Figure 3 illustrates the one-way sensitivity results
in a tornado diagram. The analyses showed that
the most influential factors on ICERs were an-
nual probability of disease progression and 
mortality rates. In particular, the difference in
survival rates between early-stage small HCC and
late-stage large HCC was the major determinant
of effectiveness in terms of deaths averted and
LYS. The results highlight the importance of
mortality reduction by the intervention and dis-
ease prevalence in a screening intervention.
Comparisons were also made between the dis-
ease progression assumptions used in the present
study and other previous studies by using multi-
variate sensitivity analysis (Table 5).8,16,22,36,46,47
A more favorable ICER was achieved
(NT$372,000/LYS) with the HCC survival rates
from a Cochrane systematic review study, com-
pared with the base case of our analysis.42 A simi-
lar ICER result was found with two parameters,
that is, HCC mortality and percentage of small
HCCs detected by screening, from another cost-
effectiveness analysis for HCC screening in
Italy.22 However, a worse ICER was shown with
three model inputs (percentage of different ther-
apies for HCC, HCC survival rates, and cost of
HCC treatments) from another cost-effectiveness
analysis study for HCC screening in Taiwan.43
The results of the marginal analysis by “what
if” scenario analysis is presented in Table 5. Given
S.T.F. Shih, et al
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Table 4. Incremental analysis results of the 1-year decision analysis and 60-year Markov model simulation
Outcome
Total cost Incremental cost
Incremental
ICER 
measures
($NT, ($NT, Effectiveness
effectiveness
($NT/
million) million) Effect)
1-year decision analysis
Deaths averted
With intervention 73.19 3.76 99324.3 0.3 13,063,000
Without intervention 69.43 99324.0
Small HCC
With intervention 73.19 3.76 3.5 1.8 2,091,000
Without intervention 69.43 1.8
60-year Markov model simulation, both outcome and cost discount at 5%
LYS
With intervention 914.73 29.70 343,604.20 59.63 498,000
No intervention 885.04 343,544.57
QALY
With intervention 914.73 29.70 266,928.36 73.85 402,000
No intervention 885.04 266,854.51
Small HCC
With intervention 914.73 29.70 57.93 26.25 1,131,000
No intervention 885.04 31.68
ICER = incremental cost-effectiveness ration; NT$ = New Taiwan Dollars; HCC = hepatocellular carcinoma; LYS = life year saved;
QALY = quality-adjusted life year.
the current participation of stage 1 screening for
risk factor identification, a slightly worse cost-
effectiveness was obtained by expanding the
HCC surveillance rate to 50% for the organized
stage 2 screening and in current practice oppor-
tunistic screening. However, if the intervention
expanded the stage 2 screening to cover 80% 
or even 100% of high-risk individuals in the
screening intervention only, a more favorable
ICER was achieved. Such results demonstrate
that expansion of the resources invested in the
screening intervention to maintain the high-risk
individuals under regular surveillance has the
potential to be more cost-effective than investing
money in encouraging high-risk individuals to
take opportunistic screening with a sporadic 
follow-up.
Multivariate probabilistic sensitivity analysis
showed that 90% uncertainty intervals were be-
tween NT$205,000/LYS to NT$1,066,000/LYS.
The mean of NT$538,000/LYS was not much 
different from the base case point estimate of
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Figure 3. Results of one-way sensitivity analysis on key outcome inputs. 1: Stage 1 screening rate; 2: stage 2 screening
rate; 3: proportion positive for risk factors; 4: hepatocellular carcinoma (HCC) incidence in chronic hepatitis; 5: percentage
of early HCC detected in intervention; 6: cirrhosis incidence in chronic hepatitis; 7: HCC incidence in cirrhosis; 8: first
year mortality of early HCC; 9: first year mortality of late HCC; 10: cirrhosis mortality; 11: early HCC mortality; 12: late
HCC mortality.
NT$498,000/LYS, which indicated the base 
case did not significantly bias the estimate in
favor of or against the screening intervention. The
cost-effectiveness acceptability curve suggested 
that 95% of the simulated ICERs were below
NT$1,070,000 per LYS.
Discussion
The major finding of the study is that screening
HCC among high-risk individuals by the two-stage
screening strategy compared with opportunistic
screening is cost-effective, subject to the mortal-
ity of HCC detected by screening being sig-
nificantly better than that of HCC detected
clinically. The results of the ICER for the base
case, NT$498,000/LYS ($US15,600/LYS in 1997),
is considered cost-effective compared with a gener-
ally accepted ICER of $US30,000/LYS, or com-
pared with other interventions in Taiwan that
have reported ICERs from NT$7196/LYS to
$US26,750/LYS.47–50 Nevertheless, it is subject to
the opinion of health care communities in Taiwan
to determine its local acceptable shadow price of
ICER per LYS in a clinical setting.
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Table 5. Discounted ICER by scenario analysis, discount rate = 5%
Scenario
Incremental cost Incremental ICER 
Reference
($NT, million) outcome (LYS) ($NT/LYS)
Base case in the present study 29.70 59.63 498,000
Cochrane systematic reviews
Wun YT & Dickinson JA (2003) 30.68 82.49 372,000 46
Adjusted for published bias
Lowest % of small HCC in the program + 28.97 31.03 934,000 8, 16
highest small HCC mortality
Lowest large HCC mortality + the above two 28.43 14.73 1,930,000 36
Model inputs in other modeling study
Pwu RF (1993) 29.71 43.63 681,000 47
Sarasin F (1996) 30.43 62.43 487,000 22
What-if scenario
Stage 2 HCC screening expanded to 50% and 55.95 110.20 508,000
opportunistic HCC screening post program 
expanded to 50%
Stage 2 HCC screening achieved 80% and 41.79 91.93 454,000
opportunistic HCC screening post program 
remained 28.6%, as for base case
Stage 2 HCC screening achieved 100% and 47.48 107.15 443,000
opportunistic HCC screening post program 
remained 28.6%, as for base case
Stage 1 risk screening expanded to 50% 221.33 462.8 478,000
Stage 1 risk screening expanded to 50% and 258.74 562.78 460,000
stage 2 HCC screening expanded to 50%
Stage 1 risk screening achieved 50% and 270.66 584.36 463,000
stage 2 HCC screening expanded to 50% and 
opportunistic HCC screening post program 
expanded to 50%
ICER = incremental cost effectiveness ratio; NT$ = New Taiwan Dollars; LYS = life year saved; HCC = hepatocellular carcinoma.
One may argue that the ICER is misleading
because of minimum incremental costs compared
with minimum incremental outcomes, which
yields a good ICER. Given the limited health gain
from the screening intervention shown by the
study, introduction of a two-stage screening in-
tervention in Taiwan would not have a great im-
pact on the whole target population. However,
the scenario analysis results suggest a more cost-
effective way to implement HCC screening by in-
vesting the resources in a specific setting: to focus
on regular surveillance of the high-risk individuals
rather than investing the resources in a general
way to promote screening. The policy relevance
in relation to implement a cost-effective HCC
screening intervention depends upon  how 
to develop an effective way of recruiting these
high-risk individuals and how the data being
collected and managed by the program.
Our analysis demonstrates clearly that the
two-stage screening intervention is potentially
cost-effective and there is a sound case for further
investment. We also explored by scenario analy-
sis the most efficient design of a national HCC
screening program. In economic jargon, we estab-
lished both “allocative efficiency” (i.e. whether
the two-stage screening intervention should be
continued), and “technical efficiency” (i.e. how
HCC screening should be conducted). Our analy-
sis was exploratory and the results may be indica-
tive. However, the sensitivity analyses highlighted
the potential development of future HCC screen-
ing in Taiwan, by focusing on the surveillance for
HCC with an organized approach, which has been
adopted by hospitals for the two-stage screening
intervention.
Although the quality of life estimate adopted
by our analysis is consistent in utility measure-
ment, it might be less relevant to chronic hepatitis
and HCC. When comparing the utility weights of
our analysis with other quality of life estimates
specific for the diseases, it appears that the weights
in our analysis are lower than those previously re-
ported.51 In particular, the utility weight in our
analysis for decompensated cirrhosis (0.16) is
much lower than that reported previously, which
ranges from 0.6 to 0.69 by various instruments for
quality of life assessment.43–45 The lower utility
weights used in our analysis might over-estimate
the benefit of the intervention by a wider gap of
health gain between the screening intervention
and current practice opportunistic screening, when
more cases of cirrhosis occur. The change in utility
weight to the values reported in other studies
barely alters the cost-effectiveness result, because
the main outcomes of our analysis, LYS and QALYs
gained, were primarily influenced by HCC mortal-
ity. Change in the utility weight of cirrhosis 
does not have much impact on the incremental
QALYs. On the contrary, the ICER with utility
weights was reduced from NT$498,000/LYS 
to NT$402,000/QALY discounted at 5% per
annum. The results suggest that the quality of life
improvement by early detection of HCC from the
screening intervention is noteworthy. Active man-
agement and treatment for chronic hepatitis and
liver cirrhosis with more frequent follow-up delay
disease progression and improve health outcomes.
It is particularly important for future studies to ad-
dress the health benefit of improved chronic hepa-
titis and liver cirrhosis follow-up attributed to the
screening intervention by a refined model.
Currently, the major issue of screening for HCC
in high-risk groups is around the benefit of sur-
vival outcomes. Wun and Dickinson have con-
ducted a Cochrane review study of liver cancer
screening in patients with chronic hepatitis, and
have concluded that “the only argument for such
screening is that, while there is no evidence of 
effect, there is also no evidence that there is “no
effect”.46 However, greater benefit of survival 
outcomes for screened HCC has been reported 
in the studies from HCC endemic areas in
Asia.5,17,25,34,52–54 This indicates a better invest-
ment return of HCC screening in endemic areas.
This observation is also supported by our study, as
well as other cost-effectiveness studies, which indi-
cate declining ICER with increasing incidence
rates.20,22,55 The incidence and prevalence impact
on screening effectiveness also highlight the is-
sues of community-based versus hospital-based
screening. Yuen and Lai argued that the risk of
J Formos Med Assoc | 2010 • Vol 109 • No 1 51
Hepatocellular carcinoma screening in Taiwan
HCC is low with a community-based screening
program but the chance of curative treatment
should be better.55 This could justify some disap-
pointing cost-effectiveness results from studies
in lower HCC incidence populations and pa-
tients with less reserved liver function, such as
those with liver cirrhosis.20,28
Lead-time bias and length-biased sampling are
inherent to screening interventions. A lead time of
5.4 months for screening for HCC has been re-
ported.17 When compared with the difference of
life expectancy between small and large HCC,
the lead time only accounts for 10–15% of the ad-
ditional survival time in small HCC. With a
10–15% discount to adjust the lead-time bias,
the result does not significantly change the con-
clusion of the cost-effectiveness for HCC screen-
ing intervention.
One major limitation of our analysis is the
simplified assumption made for the perfect accu-
racy of the screening test (i.e. 100% sensitivity
and specificity). This excluded the false-positive
cases, and under-estimated the costs of verifying
and treating these cases. The specificity of the
screening tool, abdominal ultrasound examina-
tion, has been reported as 91–97%.51 The speci-
ficity of serum AFP increases as the chosen cut-off
level rises, and it has been reported as 90.6% at a
cut-off of 20 ng/mL.56 Screening with ultrasound
and AFP would result in 3–10% of false-positive
cases. Assuming the false-positive cases were dis-
covered through the diagnostic pathway for
HCC, the cost for each false-positive case would
be similar to the diagnostic cost, that is,
NT$20,000 in our analysis. Together with a 10%
false-positive cases and 0.3% HCC incidence rate
among high-risk individuals, this would lead to
an additional NT$2000 for each case of HCC
and NT$60 for each high-risk individual. The ad-
ditional cost associated with the false-positive
cases is minimal. Most importantly, the propor-
tion of false-positive cases would be comparable
between screening intervention and opportunis-
tic screening, given that the same screening tools
are utilized in both settings. Nevertheless, the total
cost of the false-positive cases with screening 
intervention would be greater than in current
practice because of more frequent surveillance,
although the impact of the false-positive cost on
the cost-effectiveness results would be limited
because of the minimal additional cost per case
of HCC detected.
Similar to the false-positive cases, it might
not be realistic to ignore the impact of costs and
outcomes from false-negative cases. These oc-
curred at two points along the screening inter-
vention pathway in the present study, namely,
stage 1 screening for risk factors and stage 2 HCC
screening. First, in screening intervention, the
false-negative cases without prior HBV infection
(negative for HBsAg and HBsAb tests) from stage 1
screening were recalled to the screening hospital
for confirmation, and were advised to receive
HBV vaccination to prevent future infection. 
To contain our model analysis, we did not consider
the cost and benefit associated with HBV vacci-
nation for these false-negative cases. In contrast,
it is not clear how the false-negative cases were
managed in opportunistic screening. If the same
follow-up (HBV vaccination) were applied to the
false-negative cases without prior HBV infection
as in screening intervention, there would be vir-
tually no difference in health outcomes between
the two comparators. Second, false-negative
cases that occur in the stage 2 HCC screening are
more important than those from the stage 1
screening for risk factors. Interval cancer cases
from the screening intervention are deemed to
be fewer than those from opportunistic screen-
ing as a result of more frequent surveillance.
However, we would not be able to measure the
omitted costs and outcomes without a refined
model.
One limitation of the present study was lack
of access to the operational costs for screening
intervention, such as fixed and overhead costs,
which might be significantly different between
private and public administration. This could pose
a considerable cost shift if the intervention were
administered by the government through public
funding. There is also the weakness of the nar-
row government perspective taken by the present
S.T.F. Shih, et al
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study. A number of considerable indirect costs
and benefits from the government perspective
were not taken into account in our model. The
costs to patients and families in time spent on 
attending the screening and travelling between
home/workplace and hospitals were excluded
from the analysis. Other costs such as treating
chronic hepatitis B and C identified by the inter-
vention were not included. Conversely, the indirect
benefit, such as better outcomes from hepatitis B
vaccination undertaken by individuals with neg-
ative results for risk factors, should not be neg-
lected. The indirect costs and benefit not formally
captured by the model might potentially change
the cost-effectiveness results. Therefore, policy
decision makers, when utilizing the study results,
should be cautious in justifying the costs/benefit
not included in our study.
In conclusion, screening for HCC with the
two-stage screening intervention in Taiwan is
considered potentially cost-effective in the target
population. Although the present results provide
insufficient evidence for the implementation of
HCC screening intervention on a national scale,
the results point to a future direction for im-
provement of HCC screening practice, which 
is focused on the high-risk individuals with 
an organized surveillance, rather than general 
promotion of sporadic screening. Further re-
search is required to provide information on
health policy judgment with a refined model,
good quality data, and a more precise program
budget assessment.
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